Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals has completed pivotal Phase 2b clinical study of its oral insulin capsule ORMD-0801 and expects to report results from this study within the coming weeks.
Subscribe to our email newsletter
Oramed Pharma said that the Phase 2b trial is a randomised, double-blind, placebo-controlled, multi-centered study, that primary evaluated the safety, and tolerability of Oramed’s oral insulin delivery technology.
The study took place in five locations throughout South Africa and was monitored by OnQ Consulting, a clinical research organization (CRO) based in Johannesburg, South Africa.
Nadav Kidron, CEO of Oramed, said: “The completion of the Phase 2b clinical trial for ORMD-0801 is a significant milestone for Oramed. We are especially thankful for the dedication of all the investigators who participated in the study.”